Fig. 4: NGFR predicts immunotherapy resistance in melanoma patients.
From: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
a Heat map of the NGFR signature on a cohort of n = 95 melanoma PDX. b Gene Set Enrichment Analysis (GSEA) of NGFR signature (“upregulated in NGFRhi”) on three parental vs. TR cell lines. c, d GSEA on two clinical datasets of patients treated with anti-PD-1 therapy. References for the source data of these databases can be found in the Methods section.
